Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr...

|About: Endologix Inc (ELGX)|By:, SA News Editor

Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr profile and smaller EVAR systems, including totally percutaneous endovascular aneurysm repair. The authorization is based on the successful outcome of it's first clinical trial, the PEVAR Trial.